Voyager Therapeutics, Inc. (VYGR) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$26.39M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$30.27M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$30.59M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$36.63M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$26.39M | (m) | $3.17M | (m) | $0.00* | -$25.84M* | (m) | $22.04M | (m) | $20.00K |
| 2026-03-31 | Reported | (m) | -$30.27M | (m) | $2.59M | (m) | $14.00K | -$33.42M | (m) | $24.60M | (m) | $14.00K |
| 2025-09-30 | Reported | (m) | -$30.59M | (m) | $13.37M | (m) | $207.00K* | -$31.05M* | (m) | $35.87M | (m) | $83.00K |
| 2025-06-30 | Reported | (m) | -$36.63M | (m) | $5.20M | (m) | $1.10M* | -$33.26M* | (m) | $31.33M | (m) | $15.00K |
| 2025-03-31 | Reported | (m) | -$34.69M | (m) | $6.47M | (m) | $658.00K | -$37.90M | (m) | $31.53M | (m) | $37.00K |
| 2024-09-30 | Reported | (m) | -$13.78M | (m) | $24.63M | (m) | $258.00K* | -$27.97M* | (m) | $30.24M | (m) | $43.00K |
| 2024-06-30 | Reported | (m) | -$15.03M | (m) | $29.58M | (m) | $967.00K* | -$31.58M* | (m) | $34.45M | (m) | $24.00K |
| 2024-03-31 | Reported | (m) | -$16.18M | (m) | $19.52M | (m) | $2.14M | $58.77M | (m) | $27.09M | (m) | $14.00K |
| 2023-09-30 | Reported | (m) | -$29.51M | (m) | $4.61M | (m) | $782.00K* | -$21.05M* | (m) | $25.86M | (m) | -$177.00K |
| 2023-06-30 | Reported | (m) | -$25.43M | (m) | $4.85M | (m) | $1.21M* | -$835.00K* | (m) | $21.98M | (m) | $59.00K |
| 2023-03-31 | Reported | (m) | $122.88M | (m) | $150.48M | (m) | $509.00K | $123.56M | (m) | $18.57M | (m) | $704.00K |
| 2022-09-30 | Reported | (m) | $14.44M | (m) | $41.09M | (m) | $278.00K* | -$16.21M* | (m) | $19.34M | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$19.37M | (m) | $712.00K | (m) | $1.24M* | -$18.48M* | (m) | $12.53M | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$21.35M | (m) | $658.00K | (m) | $38.00K | $34.43M | (m) | $14.35M | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$25.15M | (m) | $1.48M | (m) | $660.00K* | -$20.71M* | (m) | $17.91M | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$28.59M | (m) | $1.36M | (m) | $227.00K* | -$22.72M* | (m) | $19.50M | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$25.59M | (m) | $6.50M | (m) | $375.00K | -$21.29M | (m) | $22.35M | (m) | (m) |
| 2020-09-30 | Reported | (m) | $84.53M | (m) | $117.84M | (m) | $5.15M* | -$24.74M* | (m) | $25.04M | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$8.98M | (m) | $28.68M | (m) | $1.88M* | -$21.20M* | (m) | $29.42M | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$24.43M | (m) | $18.07M | (m) | $1.51M | -$28.80M | (m) | $32.29M | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$13.77M | (m) | $32.67M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$17.81M | (m) | $20.43M | (m) | $1.17M* | -$21.58M* | (m) | $29.78M | (m) | (m) |
| 2019-06-30 | Reported | (m) | $9.19M | (m) | $46.09M | (m) | $2.06M* | -$31.56M* | (m) | $28.58M | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$29.29M | (m) | $5.20M | (m) | $1.10M | $125.16M | (m) | $24.83M | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$23.16M | (m) | $2.01M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$21.15M | (m) | $2.09M | (m) | $849.00K* | -$17.65M* | (m) | $16.63M | (m) | $0.00* |
| 2018-06-30 | Reported | (m) | -$25.69M | (m) | $2.58M | (m) | $1.33M* | -$22.50M* | (m) | $16.51M | (m) | $0.00* |
| 2018-03-31 | Reported | (m) | -$21.09M | (m) | $942.00K | (m) | $1.61M | $48.61M | (m) | $14.85M | (m) | -$180.00K |
| 2017-12-31 | Reported | (m) | -$12.35M | (m) | $6.35M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | Reported | (m) | -$23.36M | (m) | $1.15M | (m) | $412.00K* | -$15.89M* | (m) | $19.56M | (m) | $0.00* |
| 2017-06-30 | Reported | (m) | -$18.64M | (m) | $1.18M | (m) | $467.00K* | -$16.34M* | (m) | $15.30M | (m) | $195.00K |
| 2017-03-31 | Reported | (m) | -$17.52M | (m) | $1.46M | (m) | $2.94M | -$14.29M | (m) | $14.07M | (m) | -$226.00K |
| 2016-12-31 | Reported | (m) | -$13.84M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | Reported | (m) | -$10.37M | (m) | (m) | (m) | $503.00K* | -$10.19M* | (m) | $10.31M | (m) | -$303.00K |
| 2016-06-30 | Reported | (m) | -$9.62M | (m) | (m) | (m) | $197.00K* | (m) | (m) | $10.48M | (m) | (m) |
| 2016-03-31 | Reported | (m) | -$7.47M | (m) | (m) | (m) | $460.00K | (m) | (m) | $8.73M | (m) | (m) |
| 2015-12-31 | Reported | (m) | -$7.44M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | Reported | (m) | -$4.02M | (m) | (m) | (m) | $259.00K* | (m) | (m) | $6.48M | (m) | (m) |
| 2015-06-30 | Reported | (m) | -$3.97M | (m) | (m) | (m) | $500.00K* | (m) | (m) | $6.46M | (m) | (m) |
| 2015-03-31 | Reported | (m) | -$4.83M | (m) | (m) | (m) | $150.00K | (m) | (m) | $5.52M | (m) | (m) |
| 2014-12-31 | Reported | (m) | -$4.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | Reported | (m) | -$3.66M | (m) | (m) | (m) | (m) | (m) | (m) | $2.40M | (m) | (m) |
| 2014-06-30 | Reported | (m) | -$3.23M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | Reported | (m) | -$2.98M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$131.84M | (m) | $40.37M | (m) | $2.60M | -$132.47M | (m) | $134.67M | (m) | $144.00K |
| 2024-12-31 | Reported | (m) | -$83.29M | (m) | $80.00M | (m) | $3.52M | -$15.31M | (m) | $127.37M | (m) | $665.00K |
| 2023-12-31 | Reported | (m) | $122.01M | (m) | $250.01M | (m) | $3.26M | $77.92M | (m) | $92.17M | (m) | $1.41M |
| 2022-12-31 | Reported | (m) | -$50.84M | (m) | $40.91M | (m) | $2.49M | -$12.51M | (m) | $60.76M | (m) | $16.00K |
| 2021-12-31 | Reported | (m) | -$73.62M | (m) | $37.41M | (m) | $1.61M | -$53.52M | (m) | $73.79M | (m) | (m) |
| 2020-12-31 | Reported | (m) | $27.38M | (m) | $171.13M | (m) | $12.10M | -$96.72M | (m) | $108.75M | (m) | (m) |
| 2020-09-30 | Rolling | (m) | $37.34M* | (m) | $197.26M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | Rolling | (m) | -$64.99M* | (m) | $99.86M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | Rolling | (m) | -$46.82M* | (m) | $117.26M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$51.68M | (m) | $104.39M | (m) | $7.72M | $48.67M | (m) | $119.73M | (m) | (m) |
| 2019-12-31 | Rolling | (m) | -$51.68M* | (m) | $104.39M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | Rolling | (m) | -$61.07M* | (m) | $73.72M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | Rolling | (m) | -$64.41M* | (m) | $55.39M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | Rolling | (m) | -$99.30M* | (m) | $11.87M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$91.09M | (m) | $7.62M | (m) | $4.30M | -$15.89M | (m) | $64.91M | (m) | -$180.00K |
| 2018-12-31 | Rolling | (m) | -$91.09M* | (m) | $7.62M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | Rolling | (m) | -$80.28M* | (m) | $11.96M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | Rolling | (m) | -$82.49M* | (m) | $11.01M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | Rolling | (m) | -$75.43M* | (m) | $9.61M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | Reported | (m) | -$71.86M | (m) | $10.13M | (m) | $3.98M | -$61.35M | (m) | $62.26M | (m) | (m) |
| 2017-12-31 | Rolling | (m) | -$71.86M* | (m) | $10.13M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | Rolling | (m) | -$73.36M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | Rolling | (m) | -$60.38M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | Rolling | (m) | -$51.35M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | Reported | (m) | -$41.30M | (m) | $14.22M | (m) | $5.03M | -$42.48M | (m) | $42.25M | (m) | $52.00K |
| 2016-12-31 | Rolling | (m) | -$41.30M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | Rolling | (m) | -$34.90M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | Rolling | (m) | -$28.54M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | Rolling | (m) | -$22.89M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | Reported | (m) | -$20.25M | (m) | (m) | (m) | $1.03M | $41.30M | (m) | $27.68M | (m) | $0.00 |
| 2015-12-31 | Rolling | (m) | -$20.25M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | Rolling | (m) | -$17.31M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | Rolling | (m) | -$16.95M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | Rolling | (m) | -$16.21M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | Reported | (m) | -$14.37M | (m) | (m) | (m) | $2.99M | (m) | (m) | $8.90M | (m) | (m) |
| 2014-12-31 | Rolling | (m) | -$14.37M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |